SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
294 39 0 TRIL
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
219Thx. I suppose the lottery ticket pricing reflects the DLBCL uncertainty but nosemi_infinite -10/8/2018
218I can't comment intelligently on CAILS as an endpoint - just haven't resBiomaven-10/8/2018
217I don't have an opinion about the reasonableness of the seeking alpha articlsemi_infinite -10/8/2018
216Reasonable piece in TRIL - wouldn't call it particularly negative. The data Biomaven-10/7/2018
215"Seeking Alpha" article on TRIL (not very positive). Comments? PetBladerunner17-10/5/2018
214Back in May you were skeptical that the combination therapies they were testing A.J. Mullen110/3/2018
213Hi Ashley, don't remember been so negative on Exelixis (was never big fun), Miljenko Zuanic-10/3/2018
212I'm out! Finally had my order filled after chasing down the price for a couA.J. Mullen-10/3/2018
211>> now their leadership and safety advantage seems to have evaporated <scaram(o)uche-10/3/2018
210FTSV and TRIL interviews of researchers. youtube.com youtube.comsemi_infinite -10/3/2018
209Competitors coming out of the woodwork. Have we mentioned ALX Oncology's vertuck-10/1/2018
208That looks interesting to me. This paper gives some details, ncbi.nlm.nih.gov A.J. Mullen-10/1/2018
207From SITC; P99 RRx-001 is a Phase 3-Ready small molecule dual inhibitor of CD4Miljenko Zuanic110/1/2018
206One analyst thoughts FWIW. ladenburg.bluematrix.com His ranking tipranks.comsemi_infinite -6/30/2018
205O/S closer to 30M so MC of ~480M and EV ~350M assuming over allotment was fullysemi_infinite -6/29/2018
204Look at the bright side. You now have 2 additional choices for betting on CD47 semi_infinite -6/28/2018
203ATM out (to pay for combination therapies that could be kostenlos). Genius CFO/scaram(o)uche-6/28/2018
202FTSV IPO Market cap of ~ 370M and EV of ~270M. Based upon O/S of 23M.semi_infinite -6/28/2018
201FTSV - about the same MC as SURF.semi_infinite -6/21/2018
200latest FTSV S-1.... >> In addition, unless we specifically state otherwisscaram(o)uche-6/20/2018
199Bispecific, CD47 x CD20: finance.yahoo.comMiljenko Zuanic-6/20/2018
198Well, my comment was, of course, silly. Lotsa shares, any category, that donscaram(o)uche-6/11/2018
197Here’s another link to AWM’s filings re TRIL: fintel.io Confusing, but doesn’t BulbaMan-6/11/2018
196Corresponding increase in preferred shares, if all of that data is correct. Wouscaram(o)uche-6/11/2018
195Bulba, How does 11,000,000 drop to 954,000? Something doesn't seem right hBladerunner17-6/11/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News